BusinessBioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone ImplantBy Nasdaq OMXApr 30, 2018, 11:01 AM UTC
BusinessBioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource FairBy Nasdaq OMXApr 13, 2018, 11:19 AM UTC
BusinessBioCorRx CEO Brady Granier and Legendary Soul Man Sam Moore Appear on Fox Business Network to Discuss the Company's Naltrexone Implant, Which Helps Combat Opioid AddictionBy Nasdaq OMXApr 9, 2018, 4:25 PM UTC
BusinessBioCorRx Provides Business Update for the Full Year Ended 2017By Nasdaq OMXApr 6, 2018, 11:30 AM UTC
BusinessBioCorRx Comments on President Donald J. Trump’s Initiative to Stop Opioid AbuseBy Nasdaq OMXMar 20, 2018, 2:40 PM UTC
BusinessBioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102By Nasdaq OMXFeb 12, 2018, 2:23 PM UTC
BusinessBioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDABy Nasdaq OMXNov 28, 2016, 11:00 AM UTC
